Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B

被引：0

作者：

Agarwal, Kosh ^{[1
]}

Cheng, Pin-Nan ^{[2
]}

Liu, Chun-Jen ^{[3
,4
]}

Duan, Ran ^{[5
]}

Kolhatkar, Nikita ^{[5
]}

Mateo, Roberto ^{[5
]}

Da, Ben ^{[5
]}

Richards, Christopher ^{[5
]}

Sowah, Leonard ^{[5
]}

Fletcher, Simon ^{[5
]}

Mendez, Patricia ^{[5
]}

Chen, Chi-Yi ^{[6
]}

Chuang, Wan-Long ^{[7
]}

Holden Hsu, Yao-Chun ^{[8
,9
]}

机构：

[1] Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies, London, England

[2] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Tainan, Taiwan

[3] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan

[5] Gilead Sci Inc, Foster City, CA USA

[6] Ditmanson Med Fdn Chiayi Christian Hosp, Div Gastroenterol & Hepatol, Dept Med, Chiayi, Taiwan

[7] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan

[8] E Da Hosp, Kaohsiung, Taiwan

[9] I Shou Univ, Kaohsiung, Taiwan

来源：

JOURNAL OF HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-182

引用

页码：S1159 / S1160

页数：2

共 50 条

[41] An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation
Lee, Teng-Yu
Lai, Ping-Chin
Jeng, Long-Bin
Yu Tung-Min
Wu, Ming-Ju
Chen, Cheng-Hsu
Tsai, Shang-Feng
Cheng, Shao-Bin
Yang, Shengshun
JOURNAL OF HEPATOLOGY, 2020, 73 : S280 - S281
[42] Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study
Gambacorti-Passerini, Carlo
Orlov, Sergey
Zhang, Li
Braiteh, Fadi
Huang, Huiqiang
Esaki, Taito
Horibe, Keizo
Ahn, Jin-Seok
Beck, Joseph T.
Edenfield, William Jeffrey
Shi, Yuankai
Taylor, Matthew
Tamura, Kenji
Van Tine, Brian A.
Wu, Shang-Ju
Paolini, Jolanda
Li, Sherry
Kim, Tae Min
BLOOD, 2017, 130
[43] ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Hijiya, Nobuko
Heneghan, Mallorie
Kapoor, Shruti
Dhamal, Vishal
Hoch, Matthias
Descamps, Laurence
Cardoso, Ana Paula
Pollard, Jessica
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S346 - S347
[44] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
Morschhauser, Franck
Salles, Gilles
Le Gouill, Steven
Tilly, Herve
Thieblemont, Catherine
Bouabdallah, Krimo
Fabiani, Bettina
Menard, Cedric
Tarte, Karin
Cartron, Guillaume
Houot, Roch
BLOOD, 2018, 132 (14) : 1486 - 1494
[45] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
Janku, Filip
Hamilton, Erika P.
Mathews, Cara Amanda
Chu, Christina
Diamond, Jennifer Robinson
Hays, John L.
Arend, Rebecca Christian
Cristofanilli, Massimo
Jewell, Andrea
Reichmann, William
Kuida, Keisuke
Achour, Haroun
Ruiz-Soto, Rodrigo
Richardson, Debra L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Ahmadi, Tahamtan
Liu, Kevin
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[47] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Chari, Ajai
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Nahi, Hareth
Tang, Jie
Hellemans, Peter
Tromp, Brenda
Clemens, Pamela L.
Farnsworth, Andrew
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2018, 132
[48] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
BLOOD, 2017, 130
[49] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
Andrea Wang-Gillam
William Schelman
Stacey Ukrainskyj
Caly Chien
Martha Gonzalez
Zhao Yang
Marek Kania
Heather Yeckes-Rodin
Investigational New Drugs, 2023, 41 (6) : 851 - 860
[50] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
Wang-Gillam, Andrea
Schelman, William
Ukrainskyj, Stacey
Chien, Caly
Gonzalez, Martha
Yang, Zhao
Kania, Marek
Yeckes-Rodin, Heather
INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860

← 1 2 3 4 5 →